UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
Jesús G. Berdeja(Tennessee Oncology), Sundar Jagannath(Mount Sinai Hospital), Yunsi Olyslager(Janssen (Belgium)), Deepu Madduri(Johnson & Johnson (United States)), Enrique Zudaire(Centro de Investigación del Cáncer), Dongshu Geng, Syed Rizvi(Merck (Japan)), Fengling Fan, Marlene J. Carrasco-Alfonso, Arnob Banerjee(Johnson & Johnson (United States)), S.Z. Usmani(Levine Cancer Institute), Jordan M. Schecter(Centro de Investigación del Cáncer), Xin Wu, Tzu‐Min Yeh(Centro de Investigación del Cáncer), Indrajeet Singh(Janssen (United States)), Alicia J. Allred(Queen's University Belfast), Andrzej Jakubowiak(University of Chicago), Judith D. Goldberg(New York University)
Cited by 7
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k